FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

NINDS

Drug and asset intelligence for NINDS with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Mechanism of action

Gene Therapy

Recent signals(2)

ClinicalJune 25, 2026

Study on Pelvic Pain in Women with Endometriosis to Explore Treatment Approaches

A study sponsored by NINDS is investigating pelvic pain in women with endometriosis, focusing on hormonal and genetic factors.

ClinicalJune 20, 2026

Gene Transfer Study for Giant Axonal Neuropathy Initiated by NINDS

A clinical trial has been initiated to evaluate the safety and potential efficacy of scAAV9/JeT-GAN for treating Giant Axonal Neuropathy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— NINDS

June 25, 2026 · N/A

Topline Data

— NINDS

June 20, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Endometriosis →

Gene Therapy →

Gynecology →

Gynecology · Endometriosis →

Neurology →

Neurology · Gene Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.